Management of infusion reactions in clinical trials and beyond: the US and EU perspectives.
Monoclonal antibodies have expanded our cancer-fighting armamentarium in both the United States and Europe. While in general, monoclonal antibodies are well tolerated and do not have significant overlapping side effects with traditional cytotoxic agents, severe infusion reactions (IRs)--sometimes severe enough to be life threatening--have been reported. The pathophysiology of severe infusion reactions associated with monoclonal antibodies is poorly understood, but mechanisms are beginning to be elucidated. Geographic differences in the incidence of IRs have become apparent. Understanding the risk, recognizing the signs and symptoms, and being ready to promptly manage severe IRs are key for the clinician to avoid unnecessarily discontinuing these effective anticancer agents and prevent potentially tragic consequences for their patients. To date, clinical trials have incorporated monoclonal antibodies into combinations with standard cytotoxic regimens; it is expected that in time clinical trials will be testing promising new combinations utilizing multiple targeted agents, resulting in improved toxicity profiles and efficacy for cancer patients.
Cmelak
Anthony J
AJ
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA. anthony.cmelak@vanderbilt.edu
Lordick
Florian
F
Borner
Markus
M
Goldberg
Richard M
RM
Saif
M Wasif
MW
D000707:Anaphylaxis / Q000139:chemically induced / Q000628:therapy*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D005060:Europe; D006801:Humans; D007262:Infusions, Intravenous; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D014481:United States
D000911:Antibodies, Monoclonal